Management of Bell’s palsy in a 2-month-old following COVID-19 infection: a case report and review of the literature Authors: Amani A Bannout, Fatima H Hussein, Laith R Haddad Published: 2026 ABSTRACT AbstractBackgroundBell’s palsy (idiopathic peripheral facial nerve paralysis) is uncommon in children and is particularly rare in infants younger than one year of age. Its occurrence following viral infections, including coronavirus disease 2019 (COVID-19), is exceedingly rare. We report a case of Bell’s palsy in an infant following COVID-19 infection and provide a review of the relevant pediatric literature.Case presentationWe report the case of a 2-month-old female infant who developed left-sided facial weakness shortly after a COVID-19 infection. She had previously been healthy, except for a COVID-19–positive upper respiratory infection at the age of 4 weeks. Three weeks after her infection resolved, her parents noticed the sudden onset of left facial drooping, which progressed over the following three days. A diagnosis of peripheral facial nerve palsy following COVID-19 infection was proposed.Given the absence of clear treatment guidelines for infants, management options were carefully considered. The patient was ultimately started on oral prednisolone in addition to protective eye care. She demonstrated gradual clinical improvement during treatment, and at follow-up several weeks later, complete recovery of normal facial movement was observed.ConclusionsThis case highlights that Bell’s palsy, although extremely rare in infancy, may occur following a viral infection such as COVID-19. A prompt and thorough evaluation is essential to exclude alternative causes of facial paralysis. Despite no clear guidelines or recommendations favoring corticosteroid treatment vs conservative management in this age category, a decision of pharmacologic treatment was taken. In this case, corticosteroid treatment was well tolerated, and no adverse events were observed. Further studies are needed to evaluate the correlation between COVID-19 infection and facial palsy in infants, and to further assess the efficacy and safety of oral prednisolone in this age group.Keywords: Bell’s palsy, Facial nerve palsy, Infant, COVID-19, Corticosteroids, Case report Background Bell’s palsy, or idiopathic facial paralysis, is an acute-onset lower motor neuron (peripheral) facial palsy without an identifiable infectious or noninfectious cause, including neurological, hematological, traumatic, or congenital etiologies; thus, it remains a diagnosis of exclusion [1]. Although it is the most common cause of acute peripheral facial paralysis [2, 3], it is considerably less common in the pediatric population, with an estimated incidence ranging from 2.7 to 18.8 cases per 100,000 person-years [2, 4]. This condition is particularly rare in infancy, where diagnosis and management remain challenging because of the broad differential diagnosis and limited age-specific evidence [5]. The etiology of Bell’s palsy is not fully understood. Viral triggers and immune-mediated mechanisms have been proposed, particularly as many cases are preceded by an upper respiratory infection [6]. More recently, neurological complications associated with coronavirus disease 2019 (COVID-19) have been reported; however, an association between COVID-19 and Bell’s palsy in infants has not been well established. Given the rarity of this condition in infancy and the absence of established treatment guidelines for this age group, each reported case contributes valuable clinical insight. We describe a 2-month-old infant with peripheral facial palsy following COVID-19 infection to highlight the diagnostic challenges, management considerations, and clinical outcomes, along with a review of the existing literature on Bell’s palsy in infants. Case presentation We report the case of a two-month-old female infant who presented with left-sided facial asymmetry. She was born full term via an uncomplicated vaginal delivery and had no perinatal complications. She remained well until 4 weeks of age, when she was noted to have an upper respiratory tract infection and tested positive for coronavirus disease 2019 (COVID-19). During that time, she received empiric antibiotics for presumed late-onset neonatal sepsis; however, an extensive evaluation was negative aside from the COVID-19 infection. She recovered uneventfully. Over the following month, the infant remained clinically well. Three days prior to presentation, her parents noted the sudden onset of facial asymmetry, which became more pronounced the following day and prompted medical evaluation. There were no changes in level of consciousness, limb movements, or feeding, and no seizures or other neurological symptoms. On examination in the emergency department, vital signs were within normal limits for age. Neurological examination revealed marked facial asymmetry, most evident during crying: the mouth deviated to the right, the left eye could not be fully closed, forehead wrinkling was diminished on the left, and the left nasolabial fold was flattened. No other focal neurological deficits were identified. The remainder of the physical examination was unremarkable. Given the clinical presentation, consultations were obtained from pediatric neurology, infectious diseases, hematology-oncology, and ophthalmology. A comprehensive evaluation was done to distinguish peripheral facial nerve palsy from central causes (e.g., stroke, infection, or structural lesions) and to identify any treatable etiology. Laboratory investigations, including liver function tests, complete blood count, and basic metabolic panel, were within normal limits. Infectious testing was unremarkable, including repeat respiratory polymerase chain reaction (PCR) testing for covid-19 and respiratory viral panels for influenza A/B and respiratory syncytial virus (RSV). Lumbar puncture was performed; cerebrospinal fluid analysis revealed no pleocytosis, and cultures and meningitis panel results were negative. To note that the meningitis panel does not include PCR for covid-19, which was not tested in CSF, however it includes HSV1, HSV2 and CMV that were ruled out. Although serological testing for alternative viral etiologies such as Epstein–Barr virus were not performed, the patient exhibited no clinical features suggestive of systemic viral infection, including fever, lymphadenopathy, hepatosplenomegaly, mucocutaneous findings, or feeding intolerance. The temporal association with recent COVID-19 infection, combined with a benign clinical course and absence of evolving systemic symptoms, supports a post-infectious or immune-mediated mechanism. While alternative viral causes could not be definitively excluded, they are considered unlikely based on the clinical presentation. Magnetic resonance imaging (MRI) of the brain and internal auditory canals demonstrated faint enhancement of the intra-temporal segment of the left facial nerve at the fundus of the internal auditory canal, consistent with neuritis. Management was carefully considered given the absence of clear evidence-based guidelines for infants of this age. Treatment options included observation alone versus medical therapy (e.g., corticosteroids, intravenous immunoglobulin [IVIG], or antiviral therapy such as acyclovir), with careful consideration of potential risks and benefits. After discussing with the patient’s parents the risks vs. benefit of starting corticosteroids especially with the lack of clear evidence-based guidelines and in light of the progressive deficit, a decision was made to initiate corticosteroid therapy. At the 4th day since symptoms onset, the patient was started on oral prednisolone at a dose of 1 mg/kg/day once daily from day 1 to day 5, then 0.8 mg/kg/day once daily on day 6, then 0.6 mg/kg/day once daily on day 7, then 0.4 mg/kg/day once daily on day 8, then 0.2 mg/kg/day once daily on day 9, then stopped. Supportive measures were implemented, particularly ocular protection to prevent corneal injury. Lubricating ophthalmic ointment was applied to the left eye, and precautions were taken to ensure eyelid closure during sleep. The infant tolerated the corticosteroid course without adverse effects. She completed a total of 10 days of prednisolone, initiated in hospital and completed at home. Over the subsequent weeks, gradual improvement in facial movement was observed. At neurology follow-up three weeks after treatment initiation, only mild residual asymmetry was noted, characterized by slight deviation of the mouth during crying, which resolved shortly thereafter. At subsequent follow-up visits, facial function had completely normalized (Fig. 1). The patient continues to do well, with regular pediatric follow-up and age-appropriate developmental progress. a Patient before prednisolone treatment. b Patient 13 months after treatment. Written informed consent was obtained from the parent Discussion and conclusions This case highlights an extremely rare occurrence of Bell’s palsy in an infant, temporally associated with a recent COVID-19 infection. Although Bell’s palsy is uncommon in pediatric patients, it is particularly rare in infants. Diagnosis in this age group is challenging, as infants cannot report subjective symptoms and clinical findings may be subtle. It is therefore essential to exclude alternative causes of facial paralysis before establishing a diagnosis of idiopathic facial nerve palsy. In our patient, an extensive evaluation was unrevealing, aside from magnetic resonance imaging (MRI) findings consistent with facial nerve inflammation, supporting a diagnosis of neuritis. This diagnostic approach aligns with the literature emphasizing that Bell’s palsy remains a diagnosis of exclusion in children [7]. Pediatric facial paralysis carries a broad differential diagnosis, including infectious etiologies (e.g., otitis media, Lyme disease), central nervous system lesions (e.g., stroke, tumors), and congenital or traumatic causes [7]. Neuroimaging and targeted laboratory investigations are therefore warranted in infants to exclude these conditions, as performed in our case. Bell’s palsy has classically been associated with viral and post-infectious mechanisms, most commonly involving herpesviruses and other respiratory pathogens. The underlying pathophysiology is thought to involve immune-mediated inflammation leading to edema of the facial nerve within the narrow facial canal, resulting in compression, ischemia, and subsequent nerve dysfunction [8]. In the context of COVID-19 infection, several pathophysiological mechanisms have been proposed to support a potential link, including post-infectious immune-mediated neuritis, microvascular ischemic injury, and possible neurotropic effects of the virus; however, the association remains uncertain, particularly in children, and should be interpreted as temporal rather than causal [9]. Zain et al. reported a 23-month-old previously healthy girl presenting with acute peripheral facial palsy in the setting of confirmed COVID-19 infection, with magnetic resonance imaging demonstrating facial nerve neuritis [10], while Iacono et al. described a 5-year-old boy with post-infectious facial palsy attributed to COVID-19 based on serological testing despite a negative nasopharyngeal swab [11]. At the population level, data remain conflicting. A recent pooled analysis suggested a higher reported incidence of facial nerve palsy during the COVID-19 pandemic compared with the pre-pandemic period; however, this observation is based on heterogeneous datasets and may be influenced by increased clinical awareness and reporting bias rather than a true causal relationship [9]. In contrast, a pediatric cohort study conducted in a high-prevalence region found no significant change in incidence and no evidence of acute or prior COVID-19 infection among affected children, arguing against a direct association in this age group [12]. Within this context, our patient demonstrated a clear temporal relationship between prior confirmed COVID-19 infection and the subsequent onset of peripheral facial nerve palsy, in the absence of alternative etiologies and with imaging findings consistent with facial nerve inflammation, favoring a post-infectious mechanism. Although post-infectious Bell’s palsy most commonly occurs within 1–2 weeks after infection, our patient presented approximately 3 weeks following COVID-19 infection. This slightly prolonged interval remains biologically plausible in the context of delayed immune-mediated neurological complications described after viral illnesses, including COVID-19 infection [13]. The very young age at presentation further distinguishes this case from previously reported pediatric cases and may represent one of the youngest reported infants with Bell’s palsy temporally associated with COVID-19 infection, thereby expanding the limited literature on neurological sequelae of COVID-19 in early infancy. Management of Bell’s palsy in children, particularly in infants, remains controversial. In adults, early initiation of corticosteroids has been shown to improve outcomes. Two large, blinded randomized controlled trials (RCTs) of corticosteroids in adults and a meta-analysis reported clinically significant improvements in the proportion of patients who reached complete recovery when treated with steroids compared with placebo [14–16]. The American Academy of Neurology’s 2012 guideline update strongly recommends steroid therapy for newly diagnosed patients [17]. On the contrary, many studies report no additional clinical benefit of prednisolone compared to placebo in the management of Bell’s palsy. The BellPIC randomized controlled trial, a pediatric study, demonstrated no significant improvement in facial nerve recovery with prednisolone compared with placebo, despite high spontaneous recovery rates in both the prednisolone and placebo groups [18]. Similarly, a large retrospective pediatric cohort study found no clear benefit of steroid therapy and reported higher rates of incomplete recovery among steroid-treated patients, likely reflecting treatment selection bias toward more severe presentations [19]. In that cohort of 88 children with idiopathic Bell’s palsy, more than 80% achieved complete recovery within two months, underscoring the generally favorable prognosis in pediatric patients [19]. More recently, a systematic review and meta-analysis by Peralta et al. also concluded that current pediatric data does not demonstrate a clear benefit of corticosteroid therapy in Bell’s palsy, highlighting the limited evidence and heterogeneity of available studies [20]. Given this uncertainty, treatment decisions in infants should be individualized. In our patient, corticosteroid therapy was initiated based on several clinical considerations, including progressive facial weakness, early presentation within the therapeutic window, and MRI evidence of facial nerve inflammation suggesting an active inflammatory process. This was a conjoint decision between the medical team and the patient’s caregivers. The dosage and tapering regimen of oral corticosteroids in our patient were based on multiple previous pediatric studies [18]. While the patient demonstrated complete recovery following corticosteroid therapy, this outcome should be interpreted cautiously, as it is not possible to distinguish the effect of treatment from the natural history of the disease, which is typically favorable. Taken together, these findings suggest that Bell’s palsy in infancy is typically a self-limited condition with an excellent prognosis, and that management should be guided primarily by severity and progression rather than expectation of altering long-term outcome. In conclusion, Bell’s palsy can occur even in very young infants following a recent viral infection, including COVID-19, although a causal relationship cannot be established. This case underscores the importance of comprehensive evaluation, recognition of the generally favorable natural history, and a cautious, individualized approach to corticosteroid therapy. Observation with supportive care is appropriate in mild cases, whereas corticosteroids may be considered in selected infants with progressive or severe deficits, acknowledging the current lack of definitive evidence. Acknowledgements Not applicable. Abbreviations American Academy of Neurology Coronavirus Disease 2019 Emergency Department Intravenous Immunoglobulin Magnetic Resonance Imaging Neonatal Intensive Care Unit Polymerase Chain Reaction Respiratory Syncytial Virus Upper Respiratory Tract Infection Authors’ contributions A.A.B. performed the literature review and helped write the manuscript. F.H.H drafted the case report and contributed to patient care. L.R.H. conceived the report, supervised the project, and critically revised the manuscript. All authors read and approved the final manuscript. Funding No funding was received. Data availability All data generated or analyzed during this study are included in this published article. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Written informed consent was obtained from the patient’s legal guardian for publication of this case report. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analyzed during this study are included in this published article.